High Tech Pharm Co Ltd (106190)

Currency in KRW
12,650
+70(+0.56%)
Closed·

106190 Financial Summary

Key Ratios

P/E Ratio11.05
Price/Book1.15
Debt / Equity6.61%
Return on Equity10.96%
Dividend Yield0.79%
EBITDA20.73B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1,187.54%
Dividend Yield
0.79%
Industry Median 0.93%
Annualised payout
100.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 15, 2025
EPS / Forecast
205.42 / --
Revenue / Forecast
15.26B / --
EPS Revisions
Last 90 days

FAQ

What were High Tech Pharm's earnings for the latest quarter?

The High Tech Pharm EPS (TTM) is 1,187.54. High Tech Pharm reported sales of 15,258.99, net income of 2,184.13, and EPS of 205.42 for the latest quarter.

What was High Tech Pharm's net income for the latest quarter?

High Tech Pharm's net income for the latest quarter was 2,184.13.

How did High Tech Pharm's performance compare year-over-year in the latest quarter?

The company's revenue moved from 19,455.22 in the previous quarter to 15,258.99 in the latest quarter, and net income moved from 3,663.23 to 2,184.13 compared to the previous quarter.

What is High Tech Pharm's net profit margin on a TTM basis?

High Tech Pharm's trailing twelve months (TTM) net profit margin is 17.69%.

How does High Tech Pharm's debt to equity ratio compare to industry standards?

High Tech Pharm's total debt-to-equity ratio is 6.61%.

What is High Tech Pharm's return on investment on a TTM basis?

High Tech Pharm's trailing twelve months (TTM) return on investment (ROI) is 10.96%.

Did High Tech Pharm gain or lose cash last quarter?

In the latest quarter, High Tech Pharm's net change in cash was 6,765.18 million.

What were High Tech Pharm's total assets and liabilities in the latest quarter?

As of the latest quarter, High Tech Pharm reported total assets of 141,150.92 million and total liabilities of 18,648.24 million.

How has High Tech Pharm's total revenue grown this year?

High Tech Pharm's total revenue was 19,455.22 in the previous quarter and 15,258.99 in the latest quarter.

What is High Tech Pharm's gross margin on a TTM basis?

High Tech Pharm's trailing twelve months (TTM) gross margin is 24.88%.

What was High Tech Pharm's revenue per share for the latest quarter?

High Tech Pharm's revenue per share for the latest quarter was 14,346.77.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.